Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.
The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.
Isenberg Jason reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Jason Isenberg reported an equity award of 5,000 shares of Common Stock. The shares were granted on March 18, 2026 under the company’s 2019 Long Term Incentive Plan at no cash cost and are his entire reported direct holding of 5,000 shares.
The 5,000 shares are restricted stock that vest after 12 months and are subject to forfeiture until they vest. All share amounts are presented on a post–1-for-10 reverse stock split basis reflecting the reverse split effected on December 15, 2025 and earlier reverse splits.
Simeonidis Harry reported acquisition or exercise transactions in this Form 4 filing.
Intelligent Bio Solutions Inc. granted Chief Executive Officer Harry Simeonidis new equity awards in the form of restricted common stock. On March 18, 2026, he received 9,150 restricted shares that vest over 48 months, and 21,350 additional restricted shares subject to both performance-based and time-based vesting conditions. These awards were issued at no cash cost under the company’s 2019 Long Term Incentive Plan and are subject to forfeiture until the vesting requirements are met. All share amounts reflect prior reverse stock splits, including a 1-for-10 split effective December 15, 2025.
Intelligent Bio Solutions Inc. announced that it has received and deployed the first shipment of its Intelligent Fingerprinting Drug Screening Readers manufactured by new partner Syrma Johari MedTech Ltd. This confirms that the strategic manufacturing partnership, first announced in December 2025, is operating as planned.
The readers, produced to ISO 13485 and MDSAP standards, are being rolled out across construction, transportation, logistics, and manufacturing customers in the U.K. and Europe, expanding the installed base ahead of planned U.S. market entry in 2026. The partnership provides access to manufacturing capacity about four times prior levels and is expected to deliver annual production cost savings of more than 40%, supporting an anticipated improvement of roughly 20 percentage points in gross margin.
The company has also doubled in-house production capacity for its lateral flow test strips, giving it greater control over critical components, faster innovation cycles, and the ability to develop cartridges with additional test lines for expanded drug panels.
Intelligent Bio Solutions Inc. reported strong growth for its fiscal second quarter ended December 31, 2025, while remaining loss-making. Revenue rose to $896,774, a 48% year-over-year increase, driven by reader sales of $246,519 (up 104%) and cartridge sales of $516,754 (up 33%).
For the first half of fiscal 2026, revenue reached $2.01 million, up 36% year-over-year, with gross profit margins improving to 49% from 39%. Despite this, the company recorded a net loss of $2.68 million for the quarter and $5.66 million for the six months.
The company closed a $10.0 million private placement with healthcare-focused institutional investors, generating $9.40 million in net proceeds received on January 2, 2026, to support working capital, its FDA 510(k) submission, and international expansion. As of December 31, 2025, total assets were $17.65 million and shareholders’ equity was $10.89 million.
Intelligent Bio Solutions Inc. reported higher revenue but continued losses for the quarter ended December 31, 2025. Revenue rose to $896,774 from $607,494 a year earlier, driven by new customers and stronger cartridge reorders, with gross margin improving to 48.69%.
Despite this growth, the company recorded a quarterly net loss attributable to Intelligent Bio Solutions of $2,677,590 and a six‑month net loss of $5,660,596. Cash and cash equivalents were $740,371 at December 31, 2025, plus a shareholder subscription receivable of $9,402,105 that was collected on January 2, 2026.
Shareholders’ equity increased to $10,889,811, supported by at‑the‑market share sales, warrant exercises, and a $10.0 million December 2025 private placement. However, management states that expected operating losses and limited cash resources raise substantial doubt about the company’s ability to continue as a going concern without additional financing.
Intelligent Bio Solutions Inc. filed a current report stating that it has issued a press release announcing preliminary, unaudited revenue results for its fiscal second quarter ended December 31, 2025. The press release is included as Exhibit 99.1.
The company clarifies that this information is being furnished, not filed, so it is not subject to certain liability provisions under U.S. securities laws and will only be incorporated into other filings if specifically referenced.
Intelligent Bio Solutions Inc. announced that it has started a clinical study program to support a new FDA 510(k) submission seeking U.S. market clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The update was shared via a furnished press release attached as an exhibit.
Intelligent Bio Solutions Inc. is registering 6,896,550 shares of common stock for resale by existing investors. These shares consist of 105,000 shares already outstanding and 6,791,550 shares issuable upon exercise of Series L Pre-Funded Warrants and Series K‑1 and K‑2 common stock purchase warrants that were issued in a December 31, 2025 private placement. The company will not receive any proceeds from the resale of these shares, but could receive up to approximately $18.87 million if all 6,791,550 warrant shares are exercised for cash.
The private placement raised about $10.0 million in gross proceeds for working capital and general corporate purposes. As of January 2, 2026, 1,216,142 shares of common stock were outstanding. The filing notes that the resale represents a large block relative to current outstanding shares and could pressure the stock price if sold quickly. The company recently completed a 1‑for‑10 reverse stock split and has regained compliance with Nasdaq’s $1.00 minimum bid price requirement.
Intelligent Bio Solutions Inc. has filed a resale registration statement covering 6,896,550 shares of common stock for selling stockholders. These shares stem from a December 31, 2025 private placement of common stock and warrants, including 105,000 already issued shares and shares underlying Series L pre-funded warrants and Series K-1 and K-2 warrants. The company received approximately $10.0 million in gross proceeds from that private placement at a combined purchase price of $4.35 per share (or pre-funded warrant) plus accompanying warrants.
The company will not receive proceeds from the resale of these shares, but could receive up to about $18.87 million if all 6,791,550 underlying warrant shares are exercised for cash at $0.01 for pre-funded warrants and $4.10 for Series K-1 and K-2 warrants. Shares outstanding were 1,216,142 as of January 2, 2026; this is a baseline figure, not the amount being offered. Intelligent Bio Solutions is an emerging growth medical technology company focused on its Intelligent Fingerprinting drug screening system and has postponed further development of its biosensor platform pending resolution of licensing issues.
Recent corporate actions include a 1-for-10 reverse stock split effective December 15, 2025, implemented to regain compliance with Nasdaq’s $1.00 minimum bid price rule, with Nasdaq subsequently confirming compliance on January 7, 2026. The prospectus notes that the large number of shares registered for resale could pressure the stock price if sold quickly and highlights ongoing risks related to maintaining Nasdaq listing standards.